| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
2'-C-methyluridine targets HCV polymerase (NS5B), the enzyme responsible for hepatitis C virus RNA replication. The compound is a uridine analog that can inhibit HCV polymerase activity. Uridine has potential antiepileptic effects and its analogs may be used to study anticonvulsant and anxiolytic activities.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, 2'-C-methyluridine exhibits HCV polymerase inhibitory activity. The compound inhibits the polymerase activity of the HCV NS5B enzyme, preventing viral RNA replication. This activity makes the compound valuable for the development of anti-HCV therapeutics.
|
| ln Vivo |
In cell-based assays, 2'-C-methyluridine may inhibit HCV replication in infected cells. As a uridine analog, the compound may also have effects on cellular uridine metabolism. The compound is used as a key intermediate in the synthesis of methylcytidine and Sofosbuvir.
|
| Enzyme Assay |
The cell-free HCV polymerase assay involves incubation of purified HCV NS5B polymerase with RNA template, NTPs (including labeled nucleotides), and the compound at various concentrations. The reaction is incubated at 37°C, and RNA synthesis is measured by incorporation of labeled nucleotides. The IC50 is determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for anti-HCV activity involve culturing HCV replicon cells or virus-infected cells and treating them with 2'-C-methyluridine at concentrations ranging from 0.1 to 100 μM. HCV replication is assessed by measuring HCV RNA levels by qRT-PCR or by measuring viral protein expression. The compound's effects on cellular uridine metabolism can also be assessed.
|
| Animal Protocol |
There is no established animal experimental protocol for 2'-C-methyluridine specifically. As a nucleoside analog with anti-HCV activity, the compound could potentially be evaluated in animal models of HCV infection. The compound is also used in the synthesis of Sofosbuvir, which has been extensively studied in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2'-C-methyluridine have not been extensively reported. As a small molecule with molecular weight of 258.23 g/mol, the compound would be expected to have reasonable bioavailability and tissue penetration. The compound is used as a key intermediate in the synthesis of Sofosbuvir, which has well-characterized pharmacokinetic properties.
|
| Toxicity/Toxicokinetics |
Toxicity data for 2'-C-methyluridine are not well documented. As a nucleoside analog, the compound may have effects on normal cells as well as virus-infected cells. Standard toxicity studies would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
2'-C-methyluridine is a research compound used as a key intermediate in the synthesis of methylcytidine类药物 and Sofosbuvir, an FDA-approved drug for hepatitis C treatment. The compound exhibits HCV polymerase inhibitory activity. It is a uridine analog and is classified as a 2'-C-methyl nucleoside. This product is intended for research and manufacturing use only.
|
| Molecular Formula |
C10H14N2O6
|
|---|---|
| Molecular Weight |
258.23
|
| Exact Mass |
258.085
|
| CAS # |
31448-54-1
|
| PubChem CID |
500903
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Melting Point |
110-112ºC
|
| Index of Refraction |
1.615
|
| LogP |
-0.85
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
411
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)O)O
|
| InChi Key |
NBKORJKMMVZAOZ-VPCXQMTMSA-N
|
| InChi Code |
InChI=1S/C10H14N2O6/c1-10(17)7(15)5(4-13)18-8(10)12-3-2-6(14)11-9(12)16/h2-3,5,7-8,13,15,17H,4H2,1H3,(H,11,14,16)/t5-,7-,8-,10-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8725 mL | 19.3626 mL | 38.7252 mL | |
| 5 mM | 0.7745 mL | 3.8725 mL | 7.7450 mL | |
| 10 mM | 0.3873 mL | 1.9363 mL | 3.8725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
